Edinburgh Centre for Endocrinology & Diabetes, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh, EH16 4SA, UK.
Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
Diabetologia. 2020 May;63(5):906-914. doi: 10.1007/s00125-020-05099-3. Epub 2020 Feb 7.
AIMS/HYPOTHESIS: We aimed to assess whether persistence of C-peptide secretion is associated with less glucose variability and fewer low-glucose events in adults with type 1 diabetes who use flash monitoring.
We performed a cross-sectional study of 290 adults attending a university teaching hospital diabetes clinic, with type 1 diabetes, who use flash monitoring and in whom a random plasma C-peptide was available in the past 2 years. Variables relating to flash monitoring were compared between individuals with low C-peptide (<10 pmol/l) and those with persistent C-peptide (either 10-200 pmol/l or 10-50 pmol/l). In addition, the relationship between self-reported hypoglycaemia and C-peptide was assessed (n = 167). Data are median (interquartile range).
Individuals with preserved C-peptide secretion (10-200 pmol/l) had shorter duration of diabetes (15 [9-24] vs 25 [15-34] years, p < 0.001) and older age at diagnosis (23 [14-28] vs 15 [9-25] years, p < 0.001), although current age did not differ in this cohort. Preserved C-peptide was associated with lower time with glucose <3.9 mmol/l (3% [2-6%] vs 5% [3-9%], p < 0.001), fewer low-glucose events per 2 week period (7 [4-10] vs 10 [5-16], p < 0.001), lower SD of glucose (3.8 [3.4-4.2] vs 4.1 [3.5-4.7] mmol/l, p = 0.017) and lower CV of glucose (38.0 [35.0-41.6] vs 41.8 [36.5-45.8], p < 0.001). These differences were also present in those with C-peptide 10-50 pmol/l and associations were independent of diabetes duration and estimated HbA in logistic regression analysis. Preserved C-peptide was also associated with lower rates of self-reported asymptomatic hypoglycaemia (8.0% vs 22.8% in the past month, p = 0.028).
CONCLUSIONS/INTERPRETATION: Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash monitoring. This suggests that individuals with preserved C-peptide may more safely achieve intensive glycaemic targets.
目的/假设:我们旨在评估在使用闪光监测的 1 型糖尿病成人中,C 肽分泌持续存在是否与血糖变异性降低和低血糖事件减少有关。
我们对 290 名在大学教学医院糖尿病诊所就诊的 1 型糖尿病成人进行了横断面研究,这些成人使用闪光监测,并且在过去 2 年内随机血浆 C 肽可用。在 C 肽水平较低(<10pmol/L)的个体与 C 肽持续存在(10-200pmol/L 或 10-50pmol/L)的个体之间比较了与闪光监测相关的变量。此外,还评估了自我报告的低血糖与 C 肽之间的关系(n=167)。数据为中位数(四分位距)。
C 肽分泌持续存在(10-200pmol/L)的个体糖尿病病程较短(15[9-24] vs 25[15-34]年,p<0.001),诊断时年龄较大(23[14-28] vs 15[9-25]岁,p<0.001),尽管在该队列中当前年龄没有差异。C 肽持续存在与血糖<3.9mmol/L 的时间百分比更低(3%[2-6%] vs 5%[3-9%],p<0.001)、每 2 周期间低血糖事件更少(7[4-10] vs 10[5-16],p<0.001)、血糖标准差更低(3.8[3.4-4.2] vs 4.1[3.5-4.7]mmol/L,p=0.017)和血糖变异系数更低(38.0[35.0-41.6] vs 41.8[36.5-45.8],p<0.001)。在 C 肽 10-50pmol/L 的个体中也存在这些差异,并且在逻辑回归分析中,这些差异独立于糖尿病病程和估计的 HbA。持续存在的 C 肽也与自我报告的无症状性低血糖发生率较低相关(过去 1 个月为 8.0% vs 22.8%,p=0.028)。
结论/解释:持续存在的 C 肽分泌与闪光监测的低血糖事件减少和血糖变异性降低有关。这表明,持续存在 C 肽的个体可能更安全地实现强化血糖目标。